Absci(NASDAQ) ABSI

Absci uses artificial intelligence to design new medicines for untreated conditions. It creates digital blueprints for drugs and tests them in labs. This approach helps find treatments for hair loss and chronic pain.

What Does Absci Build?

• ABS-201: Antibody treatment targeting the prolactin receptor for pattern hair loss and endometriosis.
• Integrated Drug Creation: Platform that uses computer models and lab testing to build new drugs.
• Origin-1: Artificial intelligence model that designs antibodies for targets with no existing treatments.
• Drug Creation Partnerships: Collaborative programs where the company discovers new drug candidates for other pharmaceutical firms.

Strategic Steps and Partners

• Initiated the HEADLINE clinical trial in December 2025 to test treatments for pattern hair loss.
• Released the Origin-1 design platform in January 2026 to target complex biological sites.
• Established drug discovery partnerships with global companies including Merck, AstraZeneca, and Almirall.
• Integrated technology from the acquisition of Denovium to add deep learning tools to its drug discovery platform.

Faster Discovery Methods

The lab-in-the-loop system connects computer predictions directly to physical laboratory experiments. This integration allows the company to validate a new drug candidate in as little as six weeks.

The Recent Numbers

• Revenue was $650,000 in Q4 2025, down 2.3% from the previous year.
• Gross profit reached negative $2.2 million in Q4 2025, an improvement of 86.6% year-over-year.
• Operating income was negative $36.1 million in Q4 2025, worsening 21.4% from the prior year.
• Free cash flow reached negative $29.1 million in Q4 2025, deepening 71.2% compared to Q4 2024.

Bottom Line

Absci has evolved from a technology developer into a clinical-stage company with its own medicine pipeline. Its artificial intelligence strategy aims to reduce the time and cost of creating biological drugs.